Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

P. Dearnaley, David; Syndikus, Isabel; Mossop, Helen; Khoo, Vincent; Birtle, Alison; Bloomfield, David; D. Graham, John; Kirkbride, Peter; Logue, John; Malik, Zafar; Money‐Kyrle, Julian; M. O’Sullivan, Joe; Panades, Miguel; Parker, Chris; Patterson, Helen; Scrase, Christopher; Staffurth, John; Stockdale, Andrew; Tremlett, Jean; Bidmead, Margaret; Mayles, Helen; Naismith, Olivia; South, C.; Gao, Annie; Cruickshank, Clare; Hassan, Shama; Pugh, Julia; Griffin, Clare; Hall, Emma

doi:10.1016/s1470-2045(16)30102-4

Public

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Published in The Lancet Oncology • Jun 22, 2016

Authors:

David P. Dearnaley

Isabel Syndikus

Helen Mossop

Abstract

BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 ...

Subject

Medicine

Prostate cancer

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!